Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

Université de Sherbrooke

$26,680.00

Design and study of materials and bioreactor culture process to fabricate a vascularized bioartificial pancreas device

FY 2010-11

Summary
In 2000, the World Health Organization estimated that over 177 millions people have diabetes, including more than 2 millions Canadians. The financial burden of diabetes and its complications on the Canadian healthcare system is enormous estimated at $13.2 billion every year. A major challenge in the treatment of Type I diabetes is the prevention of late complications, usually achieved by intensified insulin treatment. Tissue engineering of a vascularised bioartificial pancreas could become an important element in the treatment of diabetes. However, survival of cells deeply embedded in engineered tissue constructs is compromised by lack of capillary development causing necrosis. Because of this limitation, culture and growth of large tissue mass are poorly understood. Tissue engineering integrates the sciences of chemical and biotechnological engineering, biomaterials, cell biology, and transplantation to create tissue and organ substitutes. Several challenges face the development of an engineered tissue product: cell sourcing, immuno-compatibility, maintenance of sterility and uniformity during the growth process, ""scalability"" of the manufacturing process, etc. There is a need for a culture process to control cell and tissue growth. The general objective is to develop and use a co-culture process to guide the growth of a vascularized bioartificial pancreas within a defined 3-D environment. The main concept proposed here consists to use bioactive scaffolds and a bioreactor system in which operating conditions can be modulated to guide pancreatic tissue and micro-vessel formation. The methods described in this proposal are well established in Vermette's laboratory and are supported by preliminary results. High-impact publications and intellectual property (IP) will be created. This project will make a major contribution to the training of highly qualified personnel in biotechnological engineering.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
250296-2007
Name nom
Vermette, Patrick
Department département
Génie chimique et génie biotechnologique
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2007
Award amount
26680
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
4
Committee name en
Chem. & Metallurgical Eng.
Committee name fr
Génies chimique et métal.
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
4
Nb partie
5
Application title
Design and study of materials and bioreactor culture process to fabricate a vascularized bioartificial pancreas device
Keyword
NSERC
Application summary
In 2000, the World Health Organization estimated that over 177 millions people have diabetes, including more than 2 millions Canadians. The financial burden of diabetes and its complications on the Canadian healthcare system is enormous estimated at $13.2 billion every year. A major challenge in the treatment of Type I diabetes is the prevention of late complications, usually achieved by intensified insulin treatment. Tissue engineering of a vascularised bioartificial pancreas could become an important element in the treatment of diabetes. However, survival of cells deeply embedded in engineered tissue constructs is compromised by lack of capillary development causing necrosis. Because of this limitation, culture and growth of large tissue mass are poorly understood. Tissue engineering integrates the sciences of chemical and biotechnological engineering, biomaterials, cell biology, and transplantation to create tissue and organ substitutes. Several challenges face the development of an engineered tissue product: cell sourcing, immuno-compatibility, maintenance of sterility and uniformity during the growth process, ""scalability"" of the manufacturing process, etc. There is a need for a culture process to control cell and tissue growth. The general objective is to develop and use a co-culture process to guide the growth of a vascularized bioartificial pancreas within a defined 3-D environment. The main concept proposed here consists to use bioactive scaffolds and a bioreactor system in which operating conditions can be modulated to guide pancreatic tissue and micro-vessel formation. The methods described in this proposal are well established in Vermette's laboratory and are supported by preliminary results. High-impact publications and intellectual property (IP) will be created. This project will make a major contribution to the training of highly qualified personnel in biotechnological engineering.